Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2019 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile...
April 18, 2019 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA

Phase 3 primary endpoint will now be aligned with that of previous Phase 2 studyACR CRISS is a composite index (composed of multiple outcomes including mRSS) and was secondary endpoint in current...
October 22, 2018 08:00 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

Lenabasum is a first-in-class novel, synthetic oral cannabinoid designed to treat rare, serious autoimmune diseasesFavorable safety and tolerability profiles maintained with long-term chronic...
June 14, 2018 08:25 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals to Present at the JMP Securities Life Science Conference

- Live fireside chat webcast on Wednesday, June 20th at 2:30 p.m. EDT - Norwood, MA, June 14, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the...
June 13, 2018 09:29 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Presents 1-Year Systemic Sclerosis and 6-Month Dermatomyositis Data from Open-Label Extension of Phase 2 Lenabasum Studies at EULAR 2018

Multiple key efficacy outcomes further improved in open-label extensions of systemic sclerosis (SSc) and dermatomyositis (DM) Phase 2 studies Lenabasum continues to demonstrate a favorable safety...